For more than fifty years the answer to "is weed federally legal" was one word. In April 2026 it stopped being one word.
Effective April 28, 2026, a final rule moved two categories of marijuana from Schedule I to Schedule III of the Controlled Substances Act. Everything else stayed where it was.
That means the honest answer now depends on which category your cannabis falls into — and for a lot of people in California and Illinois, the same product on the same shelf can land on either side of the line.
What the April order actually did
Two categories moved, under a final rule published in the Federal Register:
Marijuana contained in an FDA-approved drug product, and marijuana subject to a state medical marijuana license — defined as a license authorizing the manufacture, distribution or dispensing of marijuana for medical purposes.
What did not move: adult-use cannabis, regardless of its status under state law. Also unmoved are synthetic tetrahydrocannabinols and unlicensed bulk cannabis. Hemp, which sits outside the definition of marijuana entirely, is unaffected — though hemp has its own federal changes landing in late 2026.
Foley Hoag's summary of the order is blunt about the boundary: if a product is not part of an FDA approval and not covered by a qualifying state medical license, it is still Schedule I.
So this was not the rescheduling of cannabis. It was the rescheduling of part of cannabis.
The split that matters in California and Illinois
Both states run medical and adult-use programs, and many dispensaries — including ours — are licensed for both.
California issues separate M-license and A-license designations, and a great many retailers, cultivators and manufacturers hold both, often serving patients and adult-use customers from the same premises. The California NORML analysis of the order describes what that produces: M-licensed operations are now Schedule III, A-licensed operations remain Schedule I, and the business operates across two federal schedules simultaneously with no precedent for that kind of split at the entity level. If you want to check what a given California retailer is actually licensed for, here is how to verify a license.
Illinois runs both programs as well, under its own rules on who may buy what and in what quantity — we cover the current Illinois purchase limits separately.
Greenspoon Marder put the consumer version of it plainly: a cannabis product obtained through a state-licensed medical dispensary is compliant with federal law, while the same product obtained under an adult-use license violates Schedule I. Under the order's text, that holds only if the dispensary is registered with the DEA, or applied within 60 days of April 28, 2026 and its application is pending, and only if the patient's certification meets the order's requirements, described below.
Read that carefully, because it is easy to over-read. It is a description of how the order draws its categories, not a promise about how any individual case would be treated. The order is months old in regulatory terms, guidance is still being written, and law firms are openly describing the dual-license situation as unresolved. Saul Ewing advises dual-license operators to separate medical and adult-use activities in operations and recordkeeping, warning that commingling could jeopardize Schedule III status for the medical side or expose the whole operation to Schedule I liability. Dickinson Wright notes the framing leaves immediate room for dispute in states that do not cleanly separate the two.
If you are weighing whether a medical card changes your federal position, that is a question for an attorney who knows your circumstances, not for a dispensary blog.
Schedule III is not legalization, and it does not fix the personal risks
This is the part most coverage skips, and it is the part that matters most if you are reading this because you are worried about your job or your immigration status.
Schedule III substances can be manufactured, distributed and dispensed — but only by entities holding a valid DEA registration and meeting all applicable requirements. Schedule III is where ketamine and anabolic steroids live. Those are prescription drugs, dispensed through a federally recognized prescription system.
State-licensed medical cannabis works differently. There is no FDA-approved prescription pathway for the flower or the gummies at a state dispensary. A physician's recommendation under state law is not a federal prescription. Instead, the April order created a separate route. State medical licensees can register with the DEA, and a state medical certification can stand in for a prescription if it is dated and signed on the day it is issued, includes the patient's full name and address, and includes the practitioner's name, address and state license number.
That distinction carries almost all of the weight in what follows. Federal rules on employment, firearms, housing and immigration mostly turn on whether your use is lawful under federal law. For adult-use cannabis, nothing changed: use is still unlawful under federal law. For medical patients, the order opened a narrow path to federally lawful use, but only under the conditions above. It changes what licensed businesses may do — the most immediate effect being relief from the Section 280E tax treatment that has long shaped how cannabis businesses handle banking and payments. For everyone outside that path, it is not a federal permission slip.
Federal employment and contractors
Unchanged. Federal agencies and many federal contractors operate drug-free workplace requirements built on federal standards, and a positive test can lead to discipline or termination regardless of what your state allows.
Nothing in the April order created a federal employment protection. If your employer answers to a federal drug-free workplace rule, assume the rule still applies.
Federally subsidized housing
Unchanged. Housing authorities administering federally subsidized programs are bound by federal rules, and possession or use in those settings can trigger eviction proceedings even where state law permits it.
Guns: the law changed here too, and it changed the other way
The old version of this article said federal law bars firearm possession by an unlawful user of controlled substances, full stop. That is no longer an accurate statement of the law.
On June 18, 2026, the Supreme Court decided United States v. Hemani, affirming the Fifth Circuit in full. The Fifth Circuit had held 18 U.S.C. § 922(g)(3) unconstitutional as applied to a sober person with no history of firearm misuse. As one summary of the ruling put it, the Court held that Americans cannot be stripped of their Second Amendment rights or prosecuted for gun possession simply because they use marijuana or other federally prohibited drugs.
Three things keep that from being the end of the story.
The statute was not struck down. It was limited. Courts have since read Hemani to leave room for prosecution accompanied by individualized proof that a particular defendant's drug use makes him a danger to himself or others. In August 2026 the Eighth Circuit allowed the government to revive cases on that footing.
The ground is still moving. Justice Thomas wrote separately to argue that section 922(g) exceeds Congress's Commerce Clause authority and to invite courts to revisit it. The Fifth Circuit is positioned to take that question up.
Form 4473 is a separate problem. The ATF form used for firearm purchases still asks about unlawful drug use, and making a false statement on it is its own federal crime, independent of anything Hemani decided about section 922(g)(3). A ruling narrowing one statute does not make it safe to lie on a federal form.
The practical read: categorical disarmament based purely on cannabis use is no longer good law after Hemani, individualized prosecutions survive, and the purchase paperwork is unresolved. This is the single most actively litigated item on this page, and anyone making a decision on it should talk to a firearms attorney rather than rely on any article — including this one.
Immigration: unchanged, and still the harshest
This is now the strictest of the five, and rescheduling did not soften it.
USCIS policy guidance, in force since April 2019 and still current, provides that violations of federal controlled substance law — including those involving marijuana — are generally a conditional bar to establishing the good moral character required for naturalization, even where the conduct would not be an offense under state law. The same guidance reaches employment in the cannabis industry.
The consequences extend past naturalization. Immigration advocates note that a finding of inadmissibility on controlled substance grounds can affect green card applications through adjustment of status or consular processing, admission at the border including re-entry by a lawful permanent resident returning from a short trip, and eligibility for various forms of relief.
An admission is often enough. You do not need a conviction.
Note why Schedule III does not help here: immigration law follows the Controlled Substances Act, and cannabis remains a controlled substance on Schedule III. The April order lets a qualifying state certification stand in for a prescription in some cases, but nothing in it changes the USCIS guidance above. If you are not a citizen, the safest position remains the one it has always been — assume federal zero tolerance, and speak to an immigration attorney before anything else.
Federal property and travel
Unchanged. State legalization stops at the property line. National parks and forests, federal courthouses and office buildings, military bases, VA facilities and airport federal areas all remain governed by federal law.
This is also where the difference between hemp and marijuana starts to matter in practice, since the two have been separate categories under federal law since 2018 and the April order did not change that.
What happens next
The broader question — whether all marijuana, including adult-use, moves to Schedule III — is still open, and the case is on hold.
An expedited administrative hearing ran from June 29 to July 15, 2026, eleven days of testimony before Chief Administrative Law Judge Derek Julius. Post-hearing briefs were filed August 17. In its brief the DEA argued that marijuana can no longer remain in Schedule I and asked the tribunal to recommend the transfer. On September 29, 2026, the judge stayed the case while he decides whether to add a new Government Accountability Office report on drug scheduling to the record.
The judge issues a recommendation to the DEA Administrator, who holds final decision authority. There is no fixed timeline, and any final action is widely expected to draw legal challenges.
So the split described on this page is the current state, not a settled one. It could collapse into a single answer, and the agency responsible has already said which answer it prefers.
